Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“I developed Abraxane and fought for years after it was acquired that the dose should be lowered. It was hard to convince the value of low dose metronomic Abraxane and finally it was lowered for pancreatic cancer and given weekly. It was (and still is) difficult to have busy oncologists understand that the fundamental difference between Abraxane (delivered in a naturally occurring Albumin nanoparticle) and Taxol (delivered in a castor oil) that the biology completely changes…
Abraxane is transported via a GP60 mediated transport mechanism through the blood vessel wall to the tumor micro environment and activates macrophages to kill the tumor as well as “exposing” the tumor through a process called DAMPS to enable NK and T cells to recognize and kill. So it’s not that we ignore the use of chemo, it’s how we use it to activate the immune system while protecting and activating the lymphocytes with Anktiva.
Connecting the dots is tough but I will keep trying!
Other articles featuring Patrick Soon-Shiong on OncoDaily.